Memorial Sloan Kettering Cancer Center

Juno Therapeutics Gmbh

Cyr De Imus

Eric L Smith

Yan Chen

Steven M Shamah

Csaba Pazmany

Semih Ullah Tareen

Jui Dutta-Simmons

Rupesh Amin

Blythe D Sather

Collin Hauskins

Melissa Works

Aye Chen

Ruth Salmon

Kimberly Harrington

Rebecca Wu

Erik Hess

Jon Jones

Audrey Olshefsky

Stefan Ponko

Mariana Cota Stirner

Provided herein are chimeric receptors, including chimeric antigen receptors (CARs), comprising BCMA-binding molecules, including anti-BCMA antibodies and antigen-binding fragments thereof, including heavy chain variable (V) regions and single-chain antibody fragments, and encoding polynucleotides. In some embodiments, the anti-BCMA chimeric receptors specifically bind to BCMA. Among the anti-BCMA-binding molecules are human antibodies, including those that compete for binding to BCMA with reference antibodies, including a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs and uses thereof including in adoptive cell therapy.

Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides

Provided herein are chimeric receptors, such as chimeric antigen receptors (CARs), comprising BCMA-binding molecules, such as anti-BCMA antibodies and antigen-binding fragments thereof, such as heavy chain variable (V) regions and single-chain antibody fragments, and encoding polynucleotides. In some embodiments, the anti-BCMA chimeric receptors specifically bind to BCMA. Among the anti-BCMA-binding molecules are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs and uses thereof such as in adoptive cell therapy.

Growing community of inventors

Seattle, WA, United States of America

Cyr De Imus